Olaparib (AZD2281, Ku-0059436)

Catalog No.S1060

Olaparib (AZD2281, Ku-0059436) Chemical Structure

Molecular Weight(MW): 434.46

Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 150 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 76 Publications

14 Customer Reviews

  •  

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 48 hours, and protein extracts were subjected to western blot analysis with the indicated antibodies.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

     

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 48 hours, and protein extracts were subjected to western blot analysis with the indicated antibodies.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 24 (A) or 12 (B) hours, subjected to staining with propidium iodide (A) or FITC-Annexin V (B), and then analyzed by flow cytometry.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Role of PARP and BER in the synergy between PTX and GMX in A549 cells. A) Cells were pre-treated +/- 1 uM olaparib (2h) then sequentially +/- 150nM PTX (24h) then +/- GMX 12nM (48h). Cells were harvested for (left) NAD+ quantification by LC-MS/MS (mean +/-SD of quadruplicates) or (right) viability by CellTiter-Glo (mean +/-SD of duplicates) B) PAR modification of proteins and γ-H2AX levels were measured in extracts treated as in A) by western blotting.

    Cancer Res 2014 74(21), 5948-54. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    Mechanism of FK866/olaparib synergy. FK866 exacerbates levels of gH2AX caused by olaparib. CAL51 cells were exposed to FK866 and/or olaparib for 48 h and cell lysates generated and immunoblotted for total and gH2AX.

    EMBO Mol Med 2012 4, 1087-1096. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    (A) Representative confocal microscopy images of nuclear γ-H2AX (red) and DAPI (blue) staining in FKO1 cells 30 minutes following irradiation. Cells pre-treated for 24hr with 1μM NanoOlaparib, olaparib, or a vehicle control before irradiation.

    Mol Cancer Ther, 2017. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • MSH3-deficient cells are sensitive to olaparib, a PARP inhibitor, and the combination with oxaliplatin. A, clonogenic survival of HCT11635, G5 without doxycycline (DOX), and G5 cells with doxycycline, which were treated with 2 μM of oxaliplatin, 2 μM of olaparib, and the combination of these two drugs. B, clonogenic survival of HT29 cells, which were treated with 1 μM oxaliplatin, 2 μM olaparib, and the combination of these two drugs.

     

     

    J Biol Chem 2011 286, 12157-12165. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    J Exp Clin Cancer Res 2013 32(1), 95. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • Logarithmic growth curves of human Burkitt lymphoma cells over 5 days with 500 nmol/l of ABT-888 and AZD-2281 in combination with 0 Gy (a), 4 Gy (b), 8 Gy (c), and 12 Gy (d) of external beam radiation. The maximal relative reduction was 65.5% of viable cells and occurred with AZD-2281 (500 nmol/l) on day 5. DMSO, dimethyl sulfoxide.

    Nucl Med Commun 2011 32, 1046-51. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Nucl Med Commun 2011 32, 1046-51. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    Number of foci detected using laser confocal microscopy and fluorescent Fluor 647 anti-H2A.X-phosphorylated (Ser139) antibody. Double-stranded breaks (red) are clearly augmented in cells incubated with 500 nmol/l of ABT-888 and 500 nmol/l of AZD-2281 compared with PBS and 1% dimethyl sulfoxide controls. Image analysis was performed using ImageJ and the ‘analyze particle’ function.

    Nucl Med Commun 2011 32, 1046–1051 . Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Olaparib inhibited cell proliferation, and CRC cells with high XRCC2 expression had higher olaparib sensitivity. The surviving fractions of SW480 cells treated with (A) 1 mM, (B) 10 mM, and (C) 50 mM olaparib were measured using CCK-8. (D) The relation between cell viability and olaparib concentration.

    Medicine (Baltimore) 2014 93(28), e294. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • in vivo suppression of PAR formation by the PARP inhibitor AZD2281 upon induction of DNA damage Primary human lung fibroblast cells (MRC-5) were pre-treated with the indicated concentration of the PARP inhibitor AZD2281 for two hours. Oxidative DNA damage was induced by 500 µM H2O2 for 10 min and cellular PARP activity was measured by immuno-staining of poly(ADP)-ribose (PAR) (right panels). The in vivo effect of PARP inhibition was compared to cells without DNA damage induction and inhibitor (control) and H2O2-treated cells without inhibitor. Average nuclear PAR staining intensities of more than 50 cells were statistically analysed by Kruskal-Wallis and the post-hoc Dunn’s Multiple Comparison tests (left panel). Asterisks indicate highly significant (p<1%) differences to H2O2-treated cells without PARP inhibitor. Thick horizontal bars mark medians and error bars the interquartile range.

    2010 Dr. David Schrmann from University of Base. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Effect of AZD 2281 on the viability of endometrial cancer cell line Hec50 and Ishikawa and ovarian cancer cell line SKOV3,Caov3 and PA-1 was detected by WST-1 method after 3 days treatment.

     

     

    2010 Dr. Xiangbing Meng of University of Iowa. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Description Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1.
Features A potent PARP inhibitor (currently in late stage clinical trials).
Targets
PARP2 [1]
(Cell-free assay)
PARP1 [1]
(Cell-free assay)
1 nM 5 nM
In vitro

Olaparib would act against BRCA1 or BRCA2 mutations. Olaparib is not sensitive to tankyrase-1 (IC50 >1 μM). Olaparib could ablate the PARP-1 activity at concentrations of 30-100 nM in SW620 cells. Olaparib is hypersensitive to BRCA1-deficient cell lines (MDA-MB-463 and HCC1937), compared with BRCA1- and BRCA2-proficient cell lines (Hs578T, MDA-MB-231, and T47D). [1] Olaparib is strongly sensitive to KB2P cells due to suppression of base excision repair by PARP inhibition, which may result in the conversion of single-strand breaks to double-strand breaks during DNA replication, thus activating BRCA2-dependent recombination pathways. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
KP3.33 M3LjNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYm0JIQ> MWfJR|UxRTVwN{C1JEDPxE1i Ml7zNVg2PTl4MUO=
KP6.3 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDJcGo1KGR? NYjUdW9wUUN3ME2xNE41OjhizszNJC=> NIO4PVkyQDV3OU[xNy=>
KP7.7 M4PSUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfaOGo1KGR? NVfj[WF7UUN3ME21O{BvVSB? NXyxTodlOTh3NUm2NVM>
KB2P3.4 NVj6b5BIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnWyOEBl MUPJR|UxRTF{NDDNJC=> MoD1NVg2PTl4MUO=
KB2P1.21 NV;KUoF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVW0JIQ> MXPJR|UxRTh7MEegcm0h NFv6OJkyQDV3OU[xNy=>
U373-MG M3zIdGN6fG:2b4jpZ{BCe3OjeR?= NXzRRXJnOSEQvF2g NHjCZWMzPCCq NYi0dWNNUW6lcnXhd4V{KHKjZHnheIlwdiC|ZX7zbZRqfmm2eR?= MWmxPFk2PDdzMh?=
T98G M3:y[GN6fG:2b4jpZ{BCe3OjeR?= M4Pq[FEh|ryPIB?= M2jGOVI1KGh? NVnIcJpmUW6lcnXhd4V{KHKjZHnheIlwdiC|ZX7zbZRqfmm2eR?= MnXGNVg6PTR5MUK=
U87-MG M3H4dmN6fG:2b4jpZ{BCe3OjeR?= NX6yN5FmOSEQvF2g MofnNlQhcA>? M4rhU2lv[3KnYYPld{Bz[WSrYYTpc44he2Wwc3n0bZZqfHl? MoO4NVg6PTR5MUK=
UVW M{\hUWN6fG:2b4jpZ{BCe3OjeR?= MXm1NFAhdk1? MVqyOEBp MmXjTY5kemWjc3XzJJJi\GmjdHnvckB{\W6|aYTpeol1gQ>? NX;VWJBPOTh7NUS3NVI>
HeLa NWm5eWFzTnWwY4Tpc44hSXO|YYm= Ml73OVAxKG6P MlzNOEBp NEDnVGFE[XW|ZYOgZUBud2Snc4Sg[IVt[XliaX6gdoVrd2mwaX7nJI9nKHKjZHnheIlwdi2rbnT1Z4VlKESQQTDidoVic3N? NHvLR5AyQDl3NEexNi=>
HeLa NFfnb5FHfW6ldHnvckBCe3OjeR?= NWXKbYRDOSEQvF2g MXeyOEBp MVrFcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDTMZBp[XOnIHHydoV{fA>? MUSxPFk2PDdzMh?=
T98G M{j5bmZ2dmO2aX;uJGF{e2G7 NF\rbHEyKM7:TTC= NIOxT3IzPCCq NIXXUJZGdmijbnPld{Bz[WSrYYTpc44ucW6mdXPl[EBUNXCqYYPlJIFzemW|dB?= NYPNXVdkOTh7NUS3NVI>
L3 MVXDfZRwfG:6aXOgRZN{[Xl? NFLaWo02KM7:TTC= MWi5OkBp M4P3R2ROW09? NGL4PYpUcWewaX\pZ4FvfGy7IHnubIljcXS|IHPlcIwhe3W{dnn2ZYw> M2r5UFIxOTJ2NEW5
Granta-519 MYLDfZRwfG:6aXOgRZN{[Xl? NYnIcZZCPSEQvF2g NVPTcWlyQTZiaB?= MXzEUXNQ M4DmeXNtcWeqdHz5JIlvcGmkaYTzJINmdGxic4Xyeol3[Wx? M{fTfFIxOTJ2NEW5
BT MWnDfZRwfG:6aXOgRZN{[Xl? NX3KbY5uPSEQvF2g MX:5OkBp M3;mZmROW09? Mn;qV4xq\2i2bImgbY5pcWKrdIOgZ4VtdCC|dYL2bZZidA>? Ml34NlAyOjR2NUm=
UPN2 MUDDfZRwfG:6aXOgRZN{[Xl? M1PRcFUh|ryPIB?= NH;hVm46PiCq M4DibmROW09? Ml3uV4xq\2i2bImgbY5pcWKrdIOgZ4VtdCC|dYL2bZZidA>? NIPv[HczODF{NES1PS=>
HBL-2 Mm\zR5l1d3SxeHnjJGF{e2G7 MkG1OUDPxE1i NIH6TlY6PiCq M4LaVmROW09? NGXXc4VUdGmpaITsfUBqdmirYnn0d{Bk\WyuIIP1dpZqfmGu M3\lT|IxOTJ2NEW5
JVM-2 NUTUOXVDS3m2b4TvfIlkKEG|c3H5 MmDoOUDPxE1i MWe5OkBp MknHSG1UVw>? MWDTcIlocHSueTDpcohq[mm2czDj[YxtKHO3co\peoFt Mn;DNlAyOjR2NUm=
Z138 MX7DfZRwfG:6aXOgRZN{[Xl? M4rOclUh|ryPIB?= MlfpPVYhcA>? MnLKSG1UVw>? M{fYOnNtcWeqdHz5JIlvcGmkaYTzJINmdGxic4Xyeol3[Wx? MX[yNFEzPDR3OR?=
RWPE NHLNXHNKdn[jc3n2[UBCe3OjeR?= Mn\uNlUh|ryP NIPQWGc1QCCq MV3EUXNQ MWPTbYdvcW[rY3HueIx6KHKnZIXj[ZMhTVKJLXTybZZmdiClZXzsJIlvfmG|aX;u MWKyNVU4PTh4NR?=
VCaP M3fo[GlvfmG|aY\lJGF{e2G7 MlLrNlUh|ryP MlXLOFghcA>? MUnEUXNQ NHHxTHpUcWewaX\pZ4FvfGy7IILl[JVk\XNiRWLHMYRzcX[nbjDj[YxtKGmwdnHzbY9v Mkj2NlE2PzV6NkW=
Mouse H2AX−/− ES Cells NFntRmVEgXSxdH;4bYMhSXO|YYm= NF:5[lIzNjVizszN MUSyNEBp MWrTbYdvcW[rY3HueIx6KGmwaHnibZR{KGOnbHygd5Vzfmm4YXy= MnrSNlM{PTV2OEm=
Mouse ATM−/− ES Cells NV[xZY9OS3m2b4TvfIlkKEG|c3H5 MoHnNk42KM7:TR?= MXSyNEBp M1LqNnNq\26rZnnjZY51dHliaX7obYJqfHNiY3XscEB{fXK4aY\hcC=> M1n2bFI{OzV3NEi5
H1650 M3Pvfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHTVoNKOjBizszN M2HIWFE1PCCq NFn2VotKSzVyPUG1MlQ4KM7:TR?= MWiyN|I{QThyOR?=
H1650PTEN+ NXq2XoZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nCUlIxKM7:TR?= NHG2dXkyPDRiaB?= MUPJR|UxRTVyLkizJO69VQ>? M3\zN|I{OjN7OEC5
PC-9 NYDkeZBOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWSyNEDPxE1? M4\2OVE1PCCq M37sS2lEPTB;NT64PEDPxE1? NELwbZUzOzJ|OUiwPS=>
PC-9PTEN− MmHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPIUmhjOjBizszN NYX3WJA3OTR2IHi= MnrQTWM2OD14LkWyJO69VQ>? NIrIPVIzOzJ|OUiwPS=>
MDA-MB-231 NEPm[o1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYe1JIRigQ>? M4DzXmlEPTB;Nj65JO69VQ>? NETYZYwzOzd4MES5Oi=>
MDA-MB-468 NX\MdmhET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYK1JIRigQ>? MWjJR|UxRTVwMDFOwG0> NWGy[ZJYOjN5NkC0PVY>
BT20 NIflS2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzwXlNOPSCmYYm= MVrJR|UxRTdwNzFOwG0> M4K4blI{PzZyNEm2
HCC1143 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYH3bHJXPSCmYYm= MYnJR|UxRTFzLkGg{txO MViyN|c3ODR7Nh?=
HCC1937 Mmr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnwdVc2KGSjeR?= MnTkTWM2OD1zMj62JO69VQ>? NIO5V5gzOzd4MES5Oi=>
Hs578t M3ryfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXm1JIRigQ>? NIT0UYxKSzVyPUWuOkDPxE1? M2Ho[|I{PzZyNEm2
Hs578t(si) NIXscFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPFR2Q2KGSjeR?= NVP3dHZ5UUN3ME23MlUh|ryP Mm\4NlM4PjB2OU[=
BT474 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTpWXg2KGSjeR?= NFXkdItKSzVyPUG5Mlgh|ryP MWGyN|c3ODR7Nh?=
JIMT1 MlzuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjzOJA2KGSjeR?= MXnJR|UxRTdwNzFOwG0> M3vEc|I{PzZyNEm2
SKBR3 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnX[FhkPSCmYYm= MVjJR|UxRTFzLkGg{txO M{XGRlI{PzZyNEm2
SUM159 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXOWY9UPSCmYYm= MmG4TWM2OD12LkKg{txO MlqxNlM4PjB2OU[=
CAMA1 NFLjb3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV[1JIRigQ>? MkPYTWM2OD1zNT64JO69VQ>? MmLNNlM4PjB2OU[=
MCF7 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXe1JIRigQ>? MWjJR|UxRTVwODFOwG0> MWKyN|c3ODR7Nh?=
T47D NF;mfY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLpOUBl[Xl? M1;sc2lEPTB;OT62JO69VQ>? M17NXVI{PzZyNEm2
HCT116 NFe2cFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknkNVAxKM7:TR?= M{nsVlQ5KGh? NVv2[Ic2TE2VTx?= M4K1bGlEPTB;Mj61JO69VSB? M2fHOVI1PTd5OUSx
SW1116 NHy3S2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXSxNFAh|ryP MVu0PEBp MX3EUXNQ NUHRNm1IUUN3ME2xNFAh|ryP MnznNlQ2Pzd7NEG=
HT29 NH;BbIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW[xNFAh|ryP NUC0VlJEPDhiaB?= NGe5VXpFVVOR NXHubnlNUUN3ME2xOE44KM7:TR?= NX7vWIpNOjR3N{e5OFE>
LoVo NGjueYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV[xNFAh|ryP M3KwZVQ5KGh? NWj6XZlJTE2VTx?= Mo\mTWM2OD1zMz60JO69VQ>? MV[yOFU4Pzl2MR?=
HCT-15 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2H2eVExOCEQvF2= NE\WNpA1QCCq NVXmXnJOTE2VTx?= Ml7GTWM2OD1zMDFOwG0> MljENlQ2Pzd7NEG=
SW48 NXzXZ4t1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjPdJAyODBizszN NEDB[WI1QCCq MVzEUXNQ Mkm5TWM2OD17LkWg{txO M{W1d|I1PTd5OUSx
C-1 MlrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLxNVAxKM7:TR?= NXWyeW1MPDhiaB?= M3XwPWROW09? Mo\nTWM2OD15Lk[g{txO NXXGWWdnOjR3N{e5OFE>
RKO MnnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLKeXIyODBizszN M3XVPFQ5KGh? NFfmT5ZFVVOR NGfMZotKSzVyPUWuPUDPxE1? Mmm3NlQ2Pzd7NEG=
HCT116 MlHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHmdJgyODBizszN MWi0PEBp M{nEXmROW09? MXjQc5RmdnSrYYTld{BUVi1|ODDjfZRwfG:6aXPpeJkh MkHtNlQ2Pzd7NEG=
SW1116 MlzxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvtfY5oOTByIN88US=> M1vLZVQ5KGh? MXnEUXNQ NYXlWY5HWG:2ZX70bYF1\XNiU16tN|gh[3m2b4TvfIlkcXS7IB?= NYXmOlRjOjR3N{e5OFE>
HT29 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHmydVAyODBizszN M{T3XVQ5KGh? NFO4UJJFVVOR MXXQc5RmdnSrYYTld{BUVi1|ODDjfZRwfG:6aXPpeJkh NELHc5EzPDV5N{m0NS=>
LoVo NV23XXhMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELUTJQyODBizszN NIHyPXY1QCCq NF3CemRFVVOR M2C1OHBwfGWwdHnheIV{KFOQLUO4JIN6fG:2b4jpZ4l1gSB? MVGyOFU4Pzl2MR?=
SW48 NYPyNYZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvv[4RVOTByIN88US=> M2TITVQ5KGh? NWG0bZJDTE2VTx?= NXfDOldlWG:2ZX70bYF1\XNiU16tN|gh[3m2b4TvfIlkcXS7IB?= NES4XokzPDV5N{m0NS=>
C-1 MnO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV[xNFAh|ryP M33uPFQ5KGh? NILxXWRFVVOR M1L0enBwfGWwdHnheIV{KFOQLUO4JIN6fG:2b4jpZ4l1gSB? MkTjNlQ2Pzd7NEG=
RKO MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFz3TXMyODBizszN M1\YRVQ5KGh? NGDuUWhFVVOR MWPQc5RmdnSrYYTld{BUVi1|ODDjfZRwfG:6aXPpeJkh MnH4NlQ2Pzd7NEG=
HCT116 NXm2RlNNTnWwY4Tpc44hSXO|YYm= NVvXVFhyOTBibl2= MV2xNkBp NVX5VHZ3TE2VTx?= M3HQTmlv[3KnYYPld{BFVkFiZH;1ZoxmNXO2cnHu[EBjemWja4OgbY5lfWOnZDDifUBUVi1|OB?= Mlf2NlQ2Pzd7NEG=
HT29 M4rtXmZ2dmO2aX;uJGF{e2G7 MoP4NVAhdk1? NVHkfVNwOTJiaB?= MXzEUXNQ MYTJcoNz\WG|ZYOgSG5CKGSxdXLs[U1{fHKjbnSgZpJm[Wu|IHnu[JVk\WRiYomgV24uOzh? NULEepJnOjR3N{e5OFE>
TE-6 MljTSpVv[3Srb36gRZN{[Xl? MW[1JO69VSB? M{HnRlEzKGh? NXLJfIlbTE2VTx?= MkfOTY5lfWOnczDHNk9OKGG{cnXzeC=> M2fzXlI1OjF7MU[0
TE-6 NF;ZW5FHfW6ldHnvckBCe3OjeR?= NHn1dmc2KM7:TTC= MUGyOEBp MVjEUXNQ M1TNbWlv[3KnYYPld{BqdiCmb4XicIUhe3S{YX7kJIJz\WGtczCoSHNDeyl? Mn7iNlQzOTlzNkS=
Hep3B MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjZOFAh|ryPIB?= M4n4e|czKGh? Mn3QSG1UVw>? M1foRnN6dmW{Z3nzeIlk[WyueTDpcohq[mm2czDj[YxtKGe{b4f0bEB4cXSqIFTIUWVS NF62bm8zPTB5Mke1Ni=>
Huh7 NWLzWnV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXnUHpMPDBizszNJC=> M4nzVlczKGh? NVvPPY5mTE2VTx?= NE\0U25UgW6ncnfpd5Rq[2GubImgbY5pcWKrdIOgZ4VtdCCpcn;3eIghf2m2aDDETG1GWQ>? MViyOVA4Ojd3Mh?=
Hep3B NEjRPVJHfW6ldHnvckBCe3OjeR?= M3PXOlQxKM7:TTC= Mki2NlQhcA>? MmCxSG1UVw>? NUiyW2F[UW6mdXPld{BTV1NicILv[JVkfGmxbjD3bZRpKESKTVXR MVGyOVA4Ojd3Mh?=
Huh7 M4DnS2Z2dmO2aX;uJGF{e2G7 MmLnOFAh|ryPIB?= MWCyOEBp MXfEUXNQ Mo\LTY5lfWOnczDSU3MheHKxZIXjeIlwdiC5aYToJGRJVUWT NI\jUHkzPTB5Mke1Ni=>
Hep3B NUnMXHAyTnWwY4Tpc44hSXO|YYm= NFixeHg1OCEQvF2g MYiyOEBp MoTSSG1UVw>? M4rLNGlv\HWlZYOgZ4VtdCCjdYTvdIhi\3lid3n0bEBFUE2HUR?= MWiyOVA4Ojd3Mh?=
Huh7 NV7J[VNbTnWwY4Tpc44hSXO|YYm= MVy0NEDPxE1i MUGyOEBp M3rHT2ROW09? NGXmbndKdmS3Y3XzJINmdGxiYYX0c5Bp[We7IIfpeIghTEiPRWG= M37SOFI2ODd{N{Wy
SGC-7901 NVO4cVNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fTeVMxyqEQvF2= MVe0PEBp NWK2UGI1TE2VTx?= NITrNm9DdG:lazDvfIFtcXCuYYTpck1qdmS3Y3XkJINmdGxiZHXheIg> M{HueFI2PzZ5MEe2
COLO-800 Mne1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknwTWM2OD1yLkS0NVY1KM7:TR?= MUTTRW5ITVJ?
EoL-1- MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTBwNU[0OFYh|ryP Mk[2V2FPT0WU
NCI-H209 NVzDe3Q3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnRcIxKSzVyPUCuPVE2PTZizszN NXi5RYZ5W0GQR1XS
ES1 NEfGfWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTtfYNKSzVyPUGuNVE1ODhizszN M{PXc3NCVkeHUh?=
NKM-1 NFfsWlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfVTWM2OD1zLkK1N|Q4KM7:TR?= MmfUV2FPT0WU
NTERA-S-cl-D1 Mn7TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfiTWM2OD1zLkOzN|QyKM7:TR?= NWTi[YFmW0GQR1XS
MHH-ES-1 NYnjOVFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHzTWM2OD1zLk[yNFY4KM7:TR?= M{DTT3NCVkeHUh?=
ES8 NYfCSnVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrkWY1KSzVyPUGuO|I1OTRizszN NFXQUJBUSU6JRWK=
NCI-H720 NXzz[IVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTJwMkC2PVkh|ryP MmnBV2FPT0WU
EW-3 NHL6Tm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVv1TFIxUUN3ME2yMlI4PTN2IN88US=> NVnZdI9iW0GQR1XS
D-566MG NULL[|E1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\WTWM2OD1{LkS0OVY5KM7:TR?= NILneYdUSU6JRWK=
697 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzD[2I4UUN3ME2yMlg1OTd|IN88US=> NELD[YJUSU6JRWK=
ES5 MnPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLrXpdKSzVyPUKuPFgyQDlizszN NIXPbopUSU6JRWK=
COLO-684 MnS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XHUGlEPTB;Mz61NVY6PiEQvF2= NX\5OGdZW0GQR1XS
ML-2 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTNwNkCwOVgh|ryP M4D4UXNCVkeHUh?=
MC-IXC MoHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonDTWM2OD1|Lk[zN|k{KM7:TR?= M1rtXHNCVkeHUh?=
DB NVyyNYp1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXr1cpNJUUN3ME2zMlY2PDR6IN88US=> M2rtbHNCVkeHUh?=
HCC2218 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXZVYt3UUN3ME2zMlc{OTB|IN88US=> MkXoV2FPT0WU
NCI-H510A MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUKy[HpMUUN3ME2zMlgzPzJ2IN88US=> MoLkV2FPT0WU
NCI-H526 M1;YVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HweGlEPTB;Mz64Olk2QCEQvF2= MkfWV2FPT0WU
MV-4-11 NVjPU|dLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorVTWM2OD12LkGzN|M1KM7:TR?= NF3zWoNUSU6JRWK=
PA-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4L2dmlEPTB;ND6yOVI6KM7:TR?= NWDIXHJVW0GQR1XS
EW-22 M1H0T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nIdmlEPTB;ND6zOVg3KM7:TR?= M3jlRXNCVkeHUh?=
KASUMI-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\rRpJKSzVyPUSuOFAyODlizszN M4XGOnNCVkeHUh?=
LU-139 M1;QXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfSfnFKSzVyPUSuO|U5OjlizszN Mn7aV2FPT0WU
SBC-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnVOWVKSzVyPUSuPFA6ODhizszN NGO3epJUSU6JRWK=
H4 MmnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvGeYlVUUN3ME20Mlg6PDR|IN88US=> MWjTRW5ITVJ?
EW-11 M2q1cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITD[W5KSzVyPUWuNFgxPzJizszN M3ThOXNCVkeHUh?=
NBsusSR NX23WlVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHIdJpKSzVyPUWuNVIxPTVizszN Ml23V2FPT0WU
RPMI-8226 NIj0R2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PJemlEPTB;NT6xOVI1PCEQvF2= NIDhSopUSU6JRWK=
DEL NF7TeYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTVwMkCwNFYh|ryP NI\qXI1USU6JRWK=
ES4 M2npSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjqVlhKSzVyPUWuOVE{QDlizszN Ml3qV2FPT0WU
GCT MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LLTGlEPTB;NT61Olg2PiEQvF2= M1qxfXNCVkeHUh?=
NCI-H1048 MoS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTVwOUeyO|Mh|ryP MWDTRW5ITVJ?
NCI-SNU-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3X6cWlEPTB;Nj6wNlIh|ryP NXjaWWwxW0GQR1XS
ES7 NVXJS3U1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTZwMEO1O|ch|ryP NUi5O4lSW0GQR1XS
SW982 MoHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITDOWZKSzVyPU[uNFkyOzdizszN MkjwV2FPT0WU
L-363 Ml72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXyXHFKSzVyPU[uN|M6PzRizszN MYHTRW5ITVJ?
HT-1080 NIX0RlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\nT3NnUUN3ME22MlQ6Pjh|IN88US=> NFj0bnZUSU6JRWK=
HAL-01 NITMfWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnn3TWM2OD14LkWxNFkh|ryP MYnTRW5ITVJ?
NB14 M2P0dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zGTWlEPTB;Nj62OFA{QSEQvF2= MUHTRW5ITVJ?
EW-13 NFvZfGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3BVWJKSzVyPU[uO|c1OjRizszN MV;TRW5ITVJ?
NY NFrXS4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTKOW5qUUN3ME22Mlk1PjB3IN88US=> NVP6VGgxW0GQR1XS
NCI-SNU-5 Mle2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvUR491UUN3ME23MlExPDN|IN88US=> NHW2VZNUSU6JRWK=
MS-1 NX3wTVBlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjiUXVKSzVyPUeuNVc1QTRizszN MlzXV2FPT0WU
EW-16 NFzRcmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTdwM{G4OlEh|ryP MWLTRW5ITVJ?
LU-65 NE\y[2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTTTWM2OD15LkS4OFE4KM7:TR?= NWrKSZdIW0GQR1XS
HGC-27 M1fLSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWn1ZYVvUUN3ME23MlczOTd|IN88US=> MoHqV2FPT0WU
CTB-1 Mn[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTdwN{[xO|Uh|ryP NIC4WFZUSU6JRWK=
5637 MkfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTdwOUK4OkDPxE1? NEi5cXpUSU6JRWK=
U251 MkPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTdwOUSwNVYh|ryP MkjqV2FPT0WU
HOS M{TLWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLyNoNEUUN3ME24MlI{ODB5IN88US=> M4jyOXNCVkeHUh?=
DOHH-2 NIHrcWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHLfJdpUUN3ME24MlI{PThizszN MofDV2FPT0WU
EW-1 NXuwXIE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\ufmlEPTB;OD6zNFA5QCEQvF2= NX7ZWpVCW0GQR1XS
BV-173 NHTsOJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\wbYtKSzVyPUiuOVU2PCEQvF2= MV\TRW5ITVJ?
8-MG-BA MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmqwTWM2OD16Lk[4PVg5KM7:TR?= NVPkS5l3W0GQR1XS
NB69 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRThwN{C5NlEh|ryP M4L0O3NCVkeHUh?=
NCI-H69 M3TnN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnTUlBXUUN3ME25MlkxQTZzIN88US=> NWrGendjW0GQR1XS
RS4-11 NGfzU4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWi0eZY5UUN3ME2xNU4zOjB6IN88US=> M4PrN3NCVkeHUh?=
ONS-76 M3PIcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jxfGlEPTB;MUGuNlk1PyEQvF2= Ml3JV2FPT0WU
SF539 NFHnV21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPRTWM2OD1zMT60PFg6KM7:TR?= MkHEV2FPT0WU
HuO-3N1 M1\Ve2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mli4TWM2OD1zMT61O|k3KM7:TR?= NYO0[lA{W0GQR1XS
NCI-H1651 NGHtbZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTF{LkOxNVUh|ryP NF7oNGRUSU6JRWK=
KARPAS-45 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnTTWM2OD1zMj6zO|Yh|ryP MlTjV2FPT0WU
SK-NEP-1 MlfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTF{LkS2NFkh|ryP NY\WVHV7W0GQR1XS
LAMA-84 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTF|LkGwPVUh|ryP NHXYRWNUSU6JRWK=
NCI-H1155 M1XCdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;DNm52UUN3ME2xN{4zQDV4IN88US=> NIizPIVUSU6JRWK=
CTV-1 NGTEWJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorpTWM2OD1zMz60OFUh|ryP MkDVV2FPT0WU
QIMR-WIL NXnXcGF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTF|Lke4NVQh|ryP Mmj6V2FPT0WU
H9 NYXteotTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH:2O5pKSzVyPUGzMlg1PzVizszN M4rKWHNCVkeHUh?=
SK-MEL-1 MnjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLFc4hKSzVyPUGzMlk{PDdizszN NELJb|VUSU6JRWK=
HD-MY-Z NIHMWVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3i1TWlEPTB;MUSuNFY{PyEQvF2= NIDtUJdUSU6JRWK=
TI-73 M3ThUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;IRYFKSzVyPUG0MlI{PTZizszN NFrmZZpUSU6JRWK=
JVM-3 NYqzOpRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTF3LkW3NVYh|ryP MV3TRW5ITVJ?
D-247MG NXLyc2RET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\CUWlEPTB;MUWuOVk{KM7:TR?= NVO4WHVUW0GQR1XS
VA-ES-BJ NGrkemxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;uTWM2OD1zNT62NFk4KM7:TR?= NVqyXYFiW0GQR1XS
NOS-1 M1nHXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrwOoJKSzVyPUG1MlY2OjJizszN NWrBXFVtW0GQR1XS
MOLT-4 NUHvZVBlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjMTWM2OD1zNj63OVIh|ryP M{\tOHNCVkeHUh?=
Mo-T NHnCcY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnVN|dDUUN3ME2xO{4xQDR7IN88US=> Mn;IV2FPT0WU
NCI-H1770 NVfPN3FTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4X1O2lEPTB;MUeuNVU1OyEQvF2= MULTRW5ITVJ?
COLO-320-HSR NIX3T4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDGTWM2OD1zNz6xPFI4KM7:TR?= MV\TRW5ITVJ?
TE-12 MlPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTF5LkewOVQh|ryP MmrIV2FPT0WU
NCI-H82 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTF5Lki3Nlgh|ryP M3v2W3NCVkeHUh?=
NEC8 MoLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXL0OmVnUUN3ME2xPE4yOzF4IN88US=> Ml;LV2FPT0WU
HSC-3 NHL2eXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7RcnZiUUN3ME2xPE44PDF2IN88US=> MkC4V2FPT0WU
NCI-H1092 NHjrXHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTF6Lke1PVUh|ryP NEO2c2pUSU6JRWK=
NCI-H292 NFXyRVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fM[mlEPTB;MUmuNFQ5QSEQvF2= NIjI[ZNUSU6JRWK=
L-428 NVPIcml3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\OTWM2OD1zOT61OVkh|ryP NVjONYpuW0GQR1XS
LU-134-A NI\CV21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1O4PGlEPTB;MUmuOVczKM7:TR?= Mo\WV2FPT0WU
GI-ME-N MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moe0TWM2OD1zOT61O|Q4KM7:TR?= NEfwe45USU6JRWK=
ALL-PO NIe0SI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoH6TWM2OD1zOT61PVczKM7:TR?= Mo[yV2FPT0WU
D-283MED MmjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlu4TWM2OD1zOT65NVUh|ryP NFrlRVBUSU6JRWK=
D-423MG NIO2XWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkG0TWM2OD1zOT65PVY4KM7:TR?= NEnPdlBUSU6JRWK=
CAKI-1 NYLETJZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYO1Wo86UUN3ME2yNE4zOjF7IN88US=> M3jxVXNCVkeHUh?=
ETK-1 NYfUUJI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zwd2lEPTB;MkCuNlYyPSEQvF2= NFPTe3RUSU6JRWK=
G-402 M2jhXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoqwTWM2OD1{MD61N|M1KM7:TR?= NInzfnZUSU6JRWK=
HL-60 NFLUdlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XGbGlEPTB;MkGuNVYyOyEQvF2= MnroV2FPT0WU
A2058 M{ftOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlyyTWM2OD1{MT60OFc4KM7:TR?= NFPHWmFUSU6JRWK=
CHP-212 NHf4OGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfCTWM2OD1{MT65NFUyKM7:TR?= MnL2V2FPT0WU
KY821 M{S0d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;UNZJkUUN3ME2yNU46PzVizszN NEjJdG5USU6JRWK=
TYK-nu MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3p[pFLUUN3ME2yNk4xPjVzIN88US=> NH7C[3ZUSU6JRWK=
JVM-2 MnrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTJ{LkK5PFMh|ryP NYnQT25JW0GQR1XS
KU812 NVXwemRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTJ{LkezNVIh|ryP MkP4V2FPT0WU
MKN28 NITVUI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{mxbWlEPTB;MkKuPVAyPSEQvF2= NU\XN5BoW0GQR1XS
ECC10 NGXYc|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofBTWM2OD1{Mz63OFEh|ryP NF;wRVhUSU6JRWK=
BHT-101 NY\sfpE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXGeJFwUUN3ME2yOE4xODB6IN88US=> NYf3O2txW0GQR1XS
DU-4475 MnrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTJ2LkOzN|ch|ryP MYnTRW5ITVJ?
769-P NUmxN|BRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWe4[YxoUUN3ME2yOE45PDZ4IN88US=> MV7TRW5ITVJ?
HEC-1 M2HyTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4f1V2lEPTB;MkWuOFQ2KM7:TR?= NUnMWFJpW0GQR1XS
MOLT-13 MoCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHvdZlKSzVyPUK1MlU{OzFizszN M{DyVHNCVkeHUh?=
8505C MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI[wR25KSzVyPUK2MlQ6PzdizszN MV;TRW5ITVJ?
GB-1 Mnz6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3BXGxKSzVyPUK2MlcyPzZizszN NWLGZnJyW0GQR1XS
SF126 Mni0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\NTWM2OD1{Nj63OlQ5KM7:TR?= M1vIXHNCVkeHUh?=
A4-Fuk MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTqPYlDUUN3ME2yO{4yOjdzIN88US=> MXXTRW5ITVJ?
OVCAR-8 NX;4foFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XMUWlEPTB;MkeuNVU{QSEQvF2= NYfMNZlPW0GQR1XS
NCI-H1304 M37uXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXpdY04UUN3ME2yO{42PCEQvF2= M3mwWHNCVkeHUh?=
GR-ST NH\PNmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTJ6LkC0O{DPxE1? MYrTRW5ITVJ?
G-401 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M124XWlEPTB;MkiuOVA6PiEQvF2= MV\TRW5ITVJ?
LXF-289 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXyNFlKSzVyPUK4MlU3PTFizszN Mn7jV2FPT0WU
DBTRG-05MG MoLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXnTWM2OD1{OD65NlA1KM7:TR?= NUfnNmxLW0GQR1XS
YKG-1 NVz2V2ZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHWO5BKSzVyPUK5Mlg3QCEQvF2= MX3TRW5ITVJ?
GAMG M17FTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTJ7Lkm5N{DPxE1? M{XL[HNCVkeHUh?=
HCT-116 MmDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnOfYlKSzVyPUOwMlA2PDhizszN MnG5V2FPT0WU
S-117 NHXZc5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\sN2lEPTB;M{GuNlI2PyEQvF2= NXPaWFBzW0GQR1XS
NCI-H1693 M2\wfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTN|Lk[1OFIh|ryP NXnmN3UxW0GQR1XS
A427 M2D1[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPLb2NMUUN3ME2zN{46QTd4IN88US=> MWHTRW5ITVJ?
HT-29 M{OxOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTN2Lk[wN|Ih|ryP NIjYPVFUSU6JRWK=
P12-ICHIKAWA NXy3No5RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTN2Lke0PVEh|ryP MmPsV2FPT0WU
CAL-51 M{jEfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF6xUHdKSzVyPUO1MlA4ODlizszN NH;EdIFUSU6JRWK=
Ramos-2G6-4C10 NXKweW5kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfwTWM2OD1|NT6yOFI2KM7:TR?= NUDQe3NnW0GQR1XS
SCH NGq4dI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1X1Z2lEPTB;M{[uOFE4PCEQvF2= MYPTRW5ITVJ?
SK-MEL-24 MnzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHr5W4lKSzVyPUO2MlkxPDRizszN MmXQV2FPT0WU
SW1573 M1fH[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkL2TWM2OD1|OD63NlE3KM7:TR?= NYDHNoxbW0GQR1XS
BALL-1 NIPle3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7hb5JKSzVyPUO5MlIyOjlizszN NX70UW9nW0GQR1XS
BE-13 M3fub2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{O3dWlEPTB;M{muN|I6KM7:TR?= M17tWHNCVkeHUh?=
GI-1 NUfoU4I6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HaZ2lEPTB;M{muPFY1PyEQvF2= MV\TRW5ITVJ?
GOTO MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrLRmVKSzVyPUO5MlkyOzlizszN M2PrSnNCVkeHUh?=
A673 NEDkZWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTRzLkCzOFMh|ryP NV\OO5R4W0GQR1XS
KG-1 NXLxOnBLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTR|LkO5OEDPxE1? MlrlV2FPT0WU
GP5d M{\6XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLVVpBKSzVyPUS0MlA3PjZizszN MXPTRW5ITVJ?
MFM-223 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjHVmNwUUN3ME20OE4yOjJ6IN88US=> Mn3PV2FPT0WU
OAW-42 NULOUZpIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;6TWM2OD12ND6yOlQ{KM7:TR?= NYjWUGdDW0GQR1XS
C8166 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrEN5RKSzVyPUS1MlA5OjJizszN MkDpV2FPT0WU
LU-99A Ml;RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\B[mlEPTB;NE[uNVMzOiEQvF2= NFLlRZpUSU6JRWK=
NCI-H23 MnO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGSyTlRKSzVyPUS2MlE4QDVizszN MoDaV2FPT0WU
HO-1-N-1 MlPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nLO2lEPTB;NEeuNFk6QCEQvF2= MlGwV2FPT0WU
A3-KAW M2\Hcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnIOHMzUUN3ME20O{4yODB5IN88US=> M3uw[3NCVkeHUh?=
CGTH-W-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jZcGlEPTB;NEeuOVA3QSEQvF2= NFvsTnZUSU6JRWK=
DJM-1 NIq3T2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jPT2lEPTB;NEeuOVQyOyEQvF2= M3W3cHNCVkeHUh?=
A101D NX[2eVB4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoH2TWM2OD12Nz62N|U4KM7:TR?= MlrHV2FPT0WU
BB30-HNC NEHLOWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrWNVNKSzVyPUS4MlMxPzJizszN NWDlW5UyW0GQR1XS
T98G MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjwT|JIUUN3ME20PE41PjN|IN88US=> MnrFV2FPT0WU
NCI-H1573 NFftOWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2Di[2lEPTB;NEmuOFQ3OiEQvF2= M1jQdnNCVkeHUh?=
MEG-01 NWr4ZnRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrlTWM2OD12OT63OFEyKM7:TR?= NW\QRpdFW0GQR1XS
WM-115 MnHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTR7LkmyNlIh|ryP MoLnV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo Combining with temozolomide, Olaparib (10 mg/kg, p.o.) significantly suppresses tumor growth in SW620 xenografts. [1] Olaparib shows great response to Brca1-/-;p53-/- mammary tumors (50 mg/kg i.p. per day), while no responses to HR-deficient Ecad-/-;p53-/- mammary tumors. Olaparib even does not show dose-limiting toxicity in tumor-bearing mice. [3] Olaparib has been used to treat with BRCA mutated tumors, such as ovarian, breast and prostate cancers. Moreover, Olaparib shows selectively inhibition to ATM (Ataxia Telangiectasia Mutated)-deficient tumor cells, which indicates to be a potential agent for treating ATM mutant lymphoid tumors. [4]

Protocol

Kinase Assay:

[1]

+ Expand

FlashPlate assay (96-well screening assay):

To columns 1 through 10, 1 μL of Olaparib (in DMSO) is added, and 1 μL DMSO only is added to the positive (POS) and negative (NEG) control wells (columns 11 and 12, respectively) of a pretreated FlashPlate. PARP-1 is diluted 1:40 in buffer (buffer B: 10% glycerol (v/v), 25 mM HEPES, 12.5 mM MgCl2,50 mM KCl, 1 mM DTT, 0.01% NP-40 (v/v), pH 7.6) and 40 μL added to all 96 wells (final PARP-1 concentration in the assay is ~1 ng/μL). The plate is sealed and shaken at RT for 15 min. Following this, 10 μL of positive reaction mix (0.2 ng/μL of double-stranded oligonucleotide [M3/M4] DNA per well, 5 μM of NAD+ final assay concentration, and 0.075 μCi 3H-NAD+ per well) is added to the appropriate wells (columns 1-11). The negative reaction mix, lacking the DNA oligonucleotide, is added to column 12 (with the mean negative control value used as the background). The plate is resealed and shaken for a further 60 min at RT to allow the reaction to continue. Then, 50 μL of ice-cold acetic acid (30%) is added to each well to stop the reaction, and the plate is sealed and shaken for a further 60 min at RT. Tritiated signal bound to the FlashPlate is then determined in counts per minute (CPM) using the TopCount plate reader.
Cell Research:

[1]

+ Expand
  • Cell lines: Breast cancer cell lines including SW620 colon, A2780 ovarian, HCC1937, Hs578T, MDA-MB-231, MDA-MB-436, and T47D
  • Concentrations: 1-300 nM
  • Incubation Time: 7-14 days
  • Method:

    The cytotoxicity of Olaparib is measured by clonogenic assay. Olaparib is dissolved in DMSO and diluted by culture media before use. The cells are seeded in six well plates and left to attach overnight. Then Olaparib is added at various concentrations and the cells are incubated for 7-14 days. After that the surviving colonies are counted for calculating the IC50.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: Brca1-/-;p53-/- mammary tumors are generated in K14cre;Brca1F/F;p53F/F mice.
  • Formulation: 50 mg/mL stocks in DMSO with 10% 2-hydroxyl-propyl-β-cyclodextrine/PBS
  • Dosages: 50 mg/kg
  • Administration: Administered via i.p. injection at 10 μL/g of body weight
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 86 mg/mL warmed (197.94 mM)
Water 0.002 mg/mL (0.0 mM)
Ethanol Insoluble
In vivo Add solvents individually and in order:
4% DMSO+30% PEG 300+ddH2O
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 434.46
Formula

C24H23FN4O3

CAS No. 763113-22-0
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01758731 Active, not recruiting Squamous Cell Carcinoma of the Head and Neck University of Colorado, Denver July 9, 2012 Phase 1
NCT02484404 Recruiting Lung Cancer|Breast Cancer|Ovarian Cancer|Colorectal Cancer|Prostate Cancer|Triple Negative Breast Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) June 4, 2015 Phase 1|Phase 2
NCT02769962 Recruiting Solid Tumors|Small Cell Lung Carcinoma|Carcinoma, Non-Small-Cell Lung|Lung Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) May 3, 2016 Phase 1|Phase 2
NCT01237067 Completed Cervical Cancer|Ovarian Cancer|Breast Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer|Endometrial Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 26, 2010 Phase 1
NCT00678132 Completed Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 24, 2008 Phase 1
NCT02121990 Active, not recruiting Ovarian Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer Memorial Sloan Kettering Cancer Center|AstraZeneca|Genentech, Inc. April 21, 2014 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I saw that the solubility of the compound for in vivo on the website had been changed, why the change has been made?

  • Answer:

    For the formulation for in vivo, the compound dissolving in 15% Captisol (former solubility) is a suspension, and it is fine for oral gavage. And now, dissolving in 4% DMSO+30% PEG 300+ddH2O is a clear solution, and is for injection.

  • Question 2:

    How long can the chemical compound be stable in DMEM at 4 ℃?

  • Answer:

    The compound is stable in DMEM at 4 degree for one week.

Related Antibodies

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Related PARP Products

Tags: buy Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) supplier | purchase Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) cost | Olaparib (AZD2281, Ku-0059436) manufacturer | order Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID